Tracking Cathie Wood: Continuing to increase positions in WeRide while parting ways with former "gene sequencing" favorites TXG and TWST

On Monday (January 26), US stocks opened higher and closed higher, with all three major indexes rising collectively. As investors sought safe havens amid rising geopolitical and fiscal risks, precious metals prices surged significantly during the day, with both gold and silver hitting new all-time highs.

Based on recent portfolio adjustments, Cathie Wood's investment style is undergoing a noticeable sector rotation:From 'pure genomics sequencing' towards 'applied AI' and 'autonomous driving'.She has not only been selling off her previous favorites in large amounts,$10x Genomics (TXG.US)$ but has also been continuously adding positions in $WeRide (WRD.US)$ and $Kodiak AI (KDK.US)$ demonstrating ARK's strong confidence in the monetization of 'physical AI' by 2026.

Direction for adding positions: Focusing on 'Autonomous Driving' and 'AI Healthcare'

ARK is heavily deploying in the autonomous driving sector, purchasing shares in autonomous driving companies $WeRide (WRD.US)$ 48,300 shares, $Kodiak AI (KDK.US)$ 47,800 shares. WeRide, as the leader in Robotaxi, ARK’s move to increase its holdings suggests optimism about the commercial turning point of unmanned driving in urban transportation scenarios. Increasing investment in Kodiak AI reflects Cathie Wood's emphasis on the niche field of 'autonomous driving trucks/logistics.' Compared to passenger vehicles, autonomous driving in logistics may offer a faster path to profitability.

Slightly increased position in $Tempus AI (TEM.US)$ 7,737 shares. This company uses AI to analyze clinical data, aligning with ARK’s investment thesis of combining 'AI + Healthcare,' which contrasts sharply with pure bioreagent companies.

Additionally, Cathie Wood continued to increase her holdings in crypto-related concepts $Bullish (BLSH.US)$ , maintaining a bullish stance on crypto financial infrastructure.

Direction for reducing positions: Parting ways with former favorite 'gene sequencing'

Cathie Wood sold $10x Genomics (TXG.US)$ 、 $Twist Bioscience (TWST.US)$ Over 60,000 shares, these two companies were once the cornerstone of ARKK, but recent consecutive reductions indicate that 'Wood' may believe the short-term growth potential of the gene sequencing industry is less compelling than AI and autonomous driving. Capital is being withdrawn from 'research tool' companies and redirected towards 'application-oriented' companies.

Additionally, some diagnostic holdings have been reduced, $Veracyte (VCYT.US)$ as well as defense stocks, $Kratos Defense & Security Solutions (KTOS.US)$ further concentrating capital advantages.

Summary

This portfolio adjustment signals an important message: ARK in 2026 places greater emphasis on 'the physical manifestation of AI.'

Whether it’s autonomous vehicles or data-driven healthcare decisions, Wood is betting on companies that can convert AI technology into tangible productivity and generate cash flow, rather than simply funding high-valuation biotech dreams.

For investors, focusing on the performance realization of the 'autonomous driving' supply chain by 2026 could be key to following ARK's strategy.

Futubull's [Opportunities Page] has launched tracking for celebrity portfolio opportunities! Choose from multiple celebrity portfolios, follow the masters' strategies with one click, precisely lock onto high-quality targets, and invest with greater confidence!

149K Views